Literature DB >> 16384997

Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the alphal subunit of lymphocyte function-associated antigen-1.

Susan M Keating1, Kevin R Clark, Lisa D Stefanich, Fred Arellano, Caroline P Edwards, Sarah C Bodary, Steven A Spencer, Thomas R Gadek, James C Marsters, Maureen H Beresini.   

Abstract

The lymphocyte function-associated antigen-1 (LFA-1) binding of a unique class of small-molecule antagonists as represented by compound 3 was analyzed in comparison to that of soluble intercellular adhesion molecule-1 (sICAM-1) and A-286982, which respectively define direct and allosteric competitive binding sites within LFA-1's inserted (I) domain. All three molecules antagonized LFA-1 binding to ICAM-1-Immunoglobulin G fusion (ICAM-1-Ig) in a competition ELISA, but only compound 3 and sICAM-1 inhibited the binding of a fluorescein-labeled analog of compound 3 to LFA-1. Compound 3 and sICAM-1 displayed classical direct competitive binding behavior with ICAM-1. Their antagonism of LFA-1 was surmountable by both ICAM-1-Ig and a fluorescein-labeled compound 3 analog. The competition of both sICAM-1 and compound 3 with ICAM-1-Ig for LFA-1 resulted in equivalent and linear Schild plots with slopes of 1.24 and 1.26, respectively. Cross-linking studies with a photoactivated analog of compound 3 localized the high-affinity small-molecule binding site to the N-terminal 507 amino acid segment of the alpha chain of LFA-1, a region that includes the I domain. In addition, cells transfected with a variant of LFA-1 lacking this I domain showed no significant binding of a fluorescein-labeled analog of compound 3 or ICAM-1-Ig. These results demonstrate that compound 3 inhibits the LFA-1/ICAM-1 binding interaction in a directly competitive manner by binding to a high-affinity site on LFA-1. This binding site overlaps with the ICAM-1 binding site on the alpha subunit of LFA-1, which has previously been localized to the I domain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384997      PMCID: PMC2242450          DOI: 10.1110/ps.051583406

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  45 in total

Review 1.  Locking a leukocyte integrin with statins.

Authors:  P S Frenette
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

2.  Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo.

Authors:  M Shimaoka; C Lu; R T Palframan; U H von Andrian; A McCormack; J Takagi; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding.

Authors:  J R Huth; E T Olejniczak; R Mendoza; H Liang; E A Harris; M L Lupher; A E Wilson; S W Fesik; D E Staunton
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties.

Authors:  G Liu; J R Huth; E T Olejniczak; R Mendoza; P DeVries; S Leitza; E B Reilly; G F Okasinski; S W Fesik; T W von Geldern
Journal:  J Med Chem       Date:  2001-04-12       Impact factor: 7.446

5.  Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead.

Authors:  G Liu; J T Link; Z Pei; E B Reilly; S Leitza; B Nguyen; K C Marsh; G F Okasinski; T W von Geldern; M Ormes; K Fowler; M Gallatin
Journal:  J Med Chem       Date:  2000-10-19       Impact factor: 7.446

6.  Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion.

Authors:  T A Kelly; D D Jeanfavre; D W McNeil; J R Woska; P L Reilly; E A Mainolfi; K M Kishimoto; G H Nabozny; R Zinter; B J Bormann; R Rothlein
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

7.  An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond.

Authors:  C Lu; M Shimaoka; M Ferzly; C Oxvig; J Takagi; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

8.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.

Authors:  G Weitz-Schmidt; K Welzenbach; V Brinkmann; T Kamata; J Kallen; C Bruns; S Cottens; Y Takada; U Hommel
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

9.  Folding and function of I domain-deleted Mac-1 and lymphocyte function-associated antigen-1.

Authors:  P Yalamanchili; C Lu; C Oxvig; T A Springer
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

10.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03
View more
  12 in total

Review 1.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

2.  A small molecule agonist of an integrin, alphaLbeta2.

Authors:  Wei Yang; Christopher V Carman; Minsoo Kim; Azucena Salas; Motomu Shimaoka; Timothy A Springer
Journal:  J Biol Chem       Date:  2006-10-05       Impact factor: 5.157

Review 3.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

Authors:  Michelle R Arkin; Yinyan Tang; James A Wells
Journal:  Chem Biol       Date:  2014-09-18

4.  Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

Authors:  Min Zhong; Thomas R Gadek; Minna Bui; Wang Shen; John Burnier; Kenneth J Barr; Emily J Hanan; Johan D Oslob; Chul H Yu; Jiang Zhu; Michelle R Arkin; Marc J Evanchik; W Mike Flanagan; Ute Hoch; Jennifer Hyde; Saileta Prabhu; Jeffrey A Silverman; Jasmin Wright
Journal:  ACS Med Chem Lett       Date:  2012-01-31       Impact factor: 4.345

Review 5.  Overview: assays for studying integrin-dependent cell adhesion.

Authors:  Alexandre Chigaev; Larry A Sklar
Journal:  Methods Mol Biol       Date:  2012

6.  Protein-Protein Interactions as New Targets for Ion Channel Drug Discovery.

Authors:  Svetla Stoilova-McPhie; Syed Ali; Fernanda Laezza
Journal:  Austin J Pharmacol Ther       Date:  2013-12-31

7.  A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.

Authors:  Hao Guo; Changrim Lee; Mihir Shah; Srikanth R Janga; Maria C Edman; Wannita Klinngam; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2018-10-23       Impact factor: 9.776

8.  Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118).

Authors:  Yan Sun; Rui Zhang; Thomas R Gadek; Charles A O'Neill; Eric Pearlman
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

9.  Real-time analysis of the inside-out regulation of lymphocyte function-associated antigen-1 revealed similarities to and differences from very late antigen-4.

Authors:  Alexandre Chigaev; Yelena Smagley; Yinan Zhang; Anna Waller; Mark K Haynes; Or Amit; Wei Wang; Richard S Larson; Larry A Sklar
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

10.  The tripeptide feG regulates the production of intracellular reactive oxygen species by neutrophils.

Authors:  Ronald D Mathison; Joseph S Davison
Journal:  J Inflamm (Lond)       Date:  2006-06-15       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.